Professor Allan Evans

Allan Evans is Professor in Pharmaceutics and Pro Vice Chancellor, Division of Health Sciences. Allan obtained his Bachelor of Pharmacy in 1982 (South Australian Institute of Technology) and completed his Ph D in pharmacology in 1989 (University of Adelaide). After his doctorate, he spent 2 years as Research Fellow in the Department of Pharmacy at the University of Manchester. His earlier research career focussed on enantioselective pharmacokinetics and in the late 1980s he was instrumental in highlighting the problems that can be encountered when the issue of chirality is ignored when investigating the pharmacokinetics of drugs. More recently, his attention has turned to investigating the mechanisms by which drugs are transported in the intestine, liver and kidney. He is also has an active interest in the pharmacology and pharmacokinetics of the endogenous compound, L-carnitine. Allan also conducts pre-clinical and clinical pharmacokinetic studies for Australian, European and North American pharmaceutical companies and holds two NHMRC grants. As of January 2009, Allan's journal publications have recieved over 1,200 literature citations. He has supported the formation of (and is a non-executive director for)two companies, PharmaQest Pty Ltd and CPR Pharma Pty Ltd.

• In vitro - in vivo correlations (drug absorption) Hepatic and renal disposition of xenobiotics Membrane transport of drugs and metabolites Enantioselectivity in clinical pharmacology Non-steroidal anti-inflammatory agents Physiologic modelling of pharmacokinetic data Transdermal drug delivery Perfused organs in pharmacokinetic research Pharmacokinetic drug interactions Pharmacology of carnitine derivatives Pharmacokinetics and Biopharmaceutics Specialised oral drug delivery systems Percutaneous absorption and transdermal drug delivery Parenteral dosage forms Clinical pharmacology of anti-rheumatic drugs

President: Australasian Pharmaceutical Sciences Association; Jan 1998 - Dec 2002

Past-president/secretary: Australasian Pharmaceutical Sciences Association; Jan 2003 - Dec 2003

Member of the Pharmaceutical Society of Australia

Assistant Editor, Australian Pharmaceutical Formulary and Handbook, 17th Edition, 18th Edition

1982 Bachelor of Pharmacy University of South Australia (formerly South Australian Institute of Technology)

1989 Doctor of Philosophy University of Adelaide, Department of Clinical and Experimental Pharmacology Title of Thesis "Enantioselectivity in Clinical Pharmacology: Theoretical Considerations and Studies with Ibuprofen"

• Carnitine - its role in maintaining skelatal and cardiac function and its pharmacokinetics
• Pharmacokinetics - modeling, statistics, simulation and prediction
• Drug absorption - oral, transdermal and mucoadhesive drug delivery systems
• Cancer prevention - skin cancer prevention using novel compounds
• Drug development - streamlining pharmaceutical development of novel dosage forms
• The placebo response

Reuter SE, Evans AM, Chace DH, Fornasini G. Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem (2008); 45(6): 585-592.

Reuter SE, Faull RJ, Ranieri E, Evans AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant; In press (Accepted November 2008).

Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population ¡V Are Australian patients missing out? Nephrology (2008); 13(1): 3-16.

Westley IS, Morris RG, Evans AM, Sallustio BC. Glucuronidation of mycophenolic acid by Wistar and Mrp2 deficient TR-rat liver microsomes. Drug Met Dispos (2008); 36(1): 46-50.

Xia W, Hsu HY, Kong L, Evans AM, Lee R. A potential application of a piezoelectric atomiser for ophthalmic drug delivery. Appl Bionics Biomech (2007); 4(1): 9-17. 30.

Fornasini G, Upton RN, Evans AM. A pharmacokinetic model for L-carnitine in patients receiving hemodialysis. Br J Clin Pharmacol (2007); 64(3): 335-345.

Xu D, Li Y, Wang J, Davey AK, Zhang S, Evans AM. The cardioprotective effect of isosteviol on rats with heart ischemia-reperfusion injury. Life Sci (2007); 80(4): 269-274.

Ma J, Wang J, Milne RW, Xu D, Davey AK, Evans AM. Isosteviol reduces plasma glucose levels in the intravenous glucose tolerance test in Zucker diabetic fatty rats. Diabetes Obes Metab (2007); 9(4): 5997-599.

Shackleford DM, Evans AM, Milne RW, Nation RL. Loading-washout studies of the stereoselective sinusoidal Uptake of (R)- and (S)-2-phenylpropionyl acyl glucuronide. Curr Drug Metab (2006); 7(7): 817-826.

Bain MA, Milne RW, Evans AM. Disposition and metabolite kinetics of oral L-carnitine in humans. J Clin Pharmacol (2006); 46(10): 1163-1170.

Bain MA, Faull R, Milne RW, Evans AM. Oral L-carnitine: Metabolite formation and hemodialysis. Curr Drug Metab (2006); 7(7): 811-816.

Bremmell K, Evans A, Prestidge CA. Deformation and nano-rheology of red blood cells: An AFM investigation. Colloids Surf B Biointerfaces (2006); 50(1): 43-48.

Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: Effect of cyclosporine. Drug Metab Dispos (2006); 34(2): 261-266

Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant (2006); 21(5): 1300-1304.

Wang J, Nation RL, Evans AM, Cox S, Li J. Determination of antiviral nucleoside analogues AM365 and AM188 in perfusate and bile of the isolated perfused rat liver using HPLC. Biomed Chromatogr (2005); 20(3): 244-250.

I am able to provide media comment in the following areas of expertise:

Discipline: Pharmacy

• bioequivalence
• generic medicines
• carnitine
• enantiomers